norfluoxetine has been researched along with Obsessive-Compulsive Disorder in 3 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ratings of symptom severity of obsessive-compulsive disorder (Yale-Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive-compulsive disorder treated with fluoxetine doses of 20 mg/day (N = 68), 40 mg/day (N = 64), and 60 mg/day (N = 68)." | 9.08 | Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? ( Cain, JW; Dominguez, RA; Koran, LM; Rush, AJ; Thiemann, S, 1996) |
| "Ratings of symptom severity of obsessive-compulsive disorder (Yale-Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive-compulsive disorder treated with fluoxetine doses of 20 mg/day (N = 68), 40 mg/day (N = 64), and 60 mg/day (N = 68)." | 5.08 | Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? ( Cain, JW; Dominguez, RA; Koran, LM; Rush, AJ; Thiemann, S, 1996) |
| "In vivo 19fluorine nuclear magnetic resonance spectroscopy was used to measure the brain concentration of fluoxetine and norfluoxetine in five patients with obsessive-compulsive disorder and three with major depression." | 3.68 | Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. ( Clancy, K; Fava, M; Flood, JG; Gonzalez, RG; Guimaraes, AR; Pearlman, JD; Puopolo, PR; Renshaw, PF; Rosenbaum, JF, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koran, LM | 1 |
| Cain, JW | 1 |
| Dominguez, RA | 1 |
| Rush, AJ | 1 |
| Thiemann, S | 1 |
| Renshaw, PF | 1 |
| Guimaraes, AR | 1 |
| Fava, M | 1 |
| Rosenbaum, JF | 1 |
| Pearlman, JD | 1 |
| Flood, JG | 1 |
| Puopolo, PR | 1 |
| Clancy, K | 1 |
| Gonzalez, RG | 1 |
| Pato, MT | 1 |
| Murphy, DL | 1 |
| DeVane, CL | 1 |
1 trial available for norfluoxetine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
2 other studies available for norfluoxetine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.
Topics: Adult; Brain; Confidence Intervals; Depressive Disorder; Female; Fluorine; Fluoxetine; Humans; Magne | 1992 |
Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation.
Topics: Fluoxetine; Humans; Obsessive-Compulsive Disorder; Time Factors | 1991 |